Physician profile
Melanie Abboud
NPI 1659994598
$2,777.46
in general payments reported to CMS, 2019-2025
26 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $883 · 2022: $924 · 2023: $501 · 2024: $364 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $970.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $600.76 | 2021-2024 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $287.37 | 2021-2024 | Mounjaro, Jardiance |
| Novo Nordisk INC | $278.75 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $269.66 | 2021-2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.38 | 2021-2025 | Synjardy, Jardiance, Glyxambi |
| Astrazeneca Pharmaceuticals Lp | $155.41 | 2021-2025 | Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $135.17 | 2021-2024 | |
| Corcept Therapeutics | $118.34 | 2024 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.05 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $72.12 | 2021-2022 | |
| Pfizer INC. | $70.07 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $68.41 | 2022-2024 | Quviviq |
| Daiichi Sankyo INC. | $64.13 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.55 | 2021-2022 | |
| Exact Sciences Corporation | $51.00 | 2023-2024 | Cologuard Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $42.65 | 2021-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $36.47 | 2021-2022 | |
| Evoke Pharma, INC. | $35.10 | 2021-2022 | |
| Amgen INC. | $31.51 | 2025 | Evenity, Otezla, Repatha |
| Radius Health, INC. | $25.42 | 2025 | |
| Nestle Healthcare Nutrition INC. | $24.60 | 2022 | |
| Amarin Pharma, INC. | $23.74 | 2021 | |
| Dexcom, INC. | $17.53 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.00 | 2024 | Rexulti |
| Hikma Pharmaceuticals USA | $15.48 | 2023 | Kloxxado, Mitigare, Ryaltris |
| Almatica Pharma LLC | $12.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Abboud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.